Amarin Corp Plc (AMRN)

[lizzy241]

Ziploc, based on the information in the preliminary prospectus China states they expect approval "some time" in 2022. See below


Commercial Plan
In December 2020, we entered into an exclusive distribution agreement with a distributor for
pilot sales of Vascepa in Hainan province according to the PRC laws and regulations regulating urgent
clinical needs for imported drugs. We aim to launch Vascepa in China in 2022. We have formed a
concrete commercial plan for achieving Vascepa’s full potential. To ensure launch success, we will
conduct KOL mapping and engage with leading medical associations. Prior to launch, we will seek to
shape relevant major clinical practical guidelines in China, including primary prevention guidelines,
lipid-managing guidelines and diabetes guidelines, to include Vascepa. We will also seek to utilize
innovative channels, including e-commerce and internet hospitals, for launch preparation. We plan to
launch targeted recruitment of sales in core cities, onboard both medical and marketing teams for
Vascepa and expand the product coverage to target hospitals. We will seek to rapidly secure NRDL
listing and establish partnerships with private insurance providers. We plan to conduct Health
Economics and Outcomes Research (HEOR) and Real-world Evidence (RWE) studies for Vascepa.